Ample clinical trials have shown that PD-1 blockade is a vital method in the management of ccRCC and therapies based on anti-PD-1 are the first-line choices for refractory patients [32, 33]. This evidence concerns the gene PDCD1 and nonpapillary renal cell carcinoma.